Pharmaceuticals and chemicals · 19/36 against 21/36 checks · to 2026-09-08
JNJ vs LLY.
Johnson & JohnsonMakes prescription drugs and medical devices, after spinning off its consumer brands.
Eli LillyMakes drugs for diabetes, obesity and cancer, led by the GLP-1 medicines Mounjaro and Zepbound.→Johnson & Johnson (JNJ) and Eli Lilly (LLY) are within reach of each other at $648.6B and $1.06T, and on the filings Eli Lilly passes more, 21 checks of 36 against 19.
Which passes more checks?
widest gap first→The two are furthest apart on Growth, where Eli Lilly passes 5 more of the six.
| JNJ | LLY | |
|---|---|---|
| Growth | 1/6 | 6/6 |
| Trend analysis | 5/6 | 1/6 |
| Shareholder returns | 2/6 | 4/6 |
| Health | 4/6 | 3/6 |
| Value | 1/6 | 1/6 |
| Quality | 6/6 | 6/6 |
| All checks | 19/36 | 21/36 |
→Johnson & Johnson turns over $97.9B to Eli Lilly's $79.7B, 1.2 times as much. Johnson & Johnson keeps 21.5% of revenue as profit against 33.5% at Eli Lilly.
Which is growing faster, JNJ or LLY?
→Eli Lilly grew revenue faster last year, +49.6% against +8.1% at Johnson & Johnson - 42 points apart.
| JNJ | LLY | |
|---|---|---|
| Revenue (TTM) | $97.9B | $79.7B |
| Revenue growth, 1 year | +8.1% | +49.6% |
| Revenue CAGR, 3 years | - | +31.7% |
| Net income (TTM) | $21.0B | $26.7B |
| Free cash flow (TTM) | $22.2B | - |
Which hands more back to owners?
→Eli Lilly pays 0.5% at today's price and Johnson & Johnson effectively pays nothing, which is the clearest difference in what each hands back.
| JNJ | LLY | |
|---|---|---|
| Dividend yield | - | 0.5% |
| Payout ratio | - | 20.2% |
| Years of unbroken dividend | - | - |
Which balance sheet is stronger?
→Johnson & Johnson carries much the lighter balance sheet, 0.58x of debt to equity against 1.62x - which matters most in the year a downturn arrives, not this one.
| JNJ | LLY | |
|---|---|---|
| Debt / equity | 0.58x | 1.62x |
| Interest coverage | 21.5x | - |
| Cash and short-term investments | $20.8B | $9.1B |
Which is cheaper?
→Johnson & Johnson is the cheaper of the two on earnings, 31.1x against 37.8x. Against their own histories, Johnson & Johnson is above its 19.6x median and Eli Lilly is above its 35.0x.
| JNJ | LLY | |
|---|---|---|
| Share price | $269.12 | $1123.91 |
| Market cap | $648.6B | $1.06T |
| P/E | 31.1x | 37.8x |
| P/E, own median own 6-year median / own 10-year median | 19.6x | 35.0x |
| P/S | 6.6x | 13.3x |
| Free cash flow yield | 3.4% | - |
Which keeps more of each sale?
→Eli Lilly keeps more of each sale: gross margin of 83.4% against 67.9%, a gap of 15 points that flows into everything below it.
| JNJ | LLY | |
|---|---|---|
| Gross margin | 67.9% | 83.4% |
| Operating margin | 22.2% | - |
| Return on equity | 24.8% | 78.8% |
Where they differ most
the checks behind the gapGrowth: Eli Lilly 5 ahead
- Outgrew its sector last year 49.6% vs 13.6% (sector 70th pct, n=254)
- Sustained growth beats its sector (3 years) 31.7% vs 14.9% (sector 70th pct, n=247)
- Profits grew last year 93.6% vs 0.0%
- Outgrew its sector last year 8.1% vs 13.6% (sector 70th pct, n=254)
- Profits grew last year -7.2% vs 0.0%
Trend analysis: Johnson & Johnson 4 ahead
- Price above the Kumo cloud $269.12 against a cloud top of $257.77
- Tenkan above the Kijun Tenkan $272.45 above the Kijun $265.14, 15 sessions since they crossed
- The Senkou cloud ahead is rising the Senkou spans already drawn for the next 26 sessions are rising
- Price above the Kumo cloud $1,123.91, inside the cloud ($1,112.57 to $1,176.93)
- Price above the Tenkan and the Kijun $1,123.91 against the Tenkan (9 sessions) at $1,174.67 and the Kijun (26) at $1,200.11
- Tenkan above the Kijun Tenkan $1,174.67 below the Kijun $1,200.11, 1 session since they crossed